Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma

Many RAS pathway inhibitors, including pan-RAF inhibitors, have shown significant anti-tumor activities in both solid and hematological tumors. The pan-RAF inhibitor, TAK-580, is a representative of the novel RAF inhibitors that act by disrupting RAF homo- or heterodimerization. In this study, we ex...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Suzuki, Rikio, Kitamura, Yuka, Nakamura, Yoshihiko, Akashi, Hibiki, Ogawa, Yoshiaki, Kawada, Hiroshi, Ando, Kiyoshi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2020
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7646837/
https://ncbi.nlm.nih.gov/pubmed/33216827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27775
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak